CY1105027T1 - Αναστολεις της βιοσυνθεσης της συνθασης του ενδοϋπεροξειδιου η της προσταγλανδινης - Google Patents

Αναστολεις της βιοσυνθεσης της συνθασης του ενδοϋπεροξειδιου η της προσταγλανδινης

Info

Publication number
CY1105027T1
CY1105027T1 CY20061100599T CY061100599T CY1105027T1 CY 1105027 T1 CY1105027 T1 CY 1105027T1 CY 20061100599 T CY20061100599 T CY 20061100599T CY 061100599 T CY061100599 T CY 061100599T CY 1105027 T1 CY1105027 T1 CY 1105027T1
Authority
CY
Cyprus
Prior art keywords
cox
inhibitors
cyclooxygenase
endoperoxide
compounds
Prior art date
Application number
CY20061100599T
Other languages
English (en)
Inventor
Lawrence A. Black
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of CY1105027T1 publication Critical patent/CY1105027T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/18—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/650905—Six-membered rings having the nitrogen atoms in the positions 1 and 2

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Η παρούσα εφεύρεση περιγράφει ενώσεις της πυριδαζινόνης οι οποίες είναι αναστολείς της κυκλοοξυγενάσης (COX) και, συγκεκριμένα, είναι επιλεκτικοί αναστολείς της κυκλοοξυγενάσης-2 (COX-2). Η COX-2 είναι η επαγόμενη ισομορφή που συνδέεται με τη φλεγμονή, σε αντίθεση με την ιδιοσυστατική ισομορφή, την κυκλοοξυγενάση-1 (COX-1), η οποία είναι ένα σημαντικό ένζυμο "βασικών λειτουργιών" σε αρκετούς ιστούς που συμπεριλαμβάνουν τον γαστρεντερικό σωλήνα (GI) και τους νεφρούς. Η επιλεκτικότητα αυτών των ενώσεων για τη COX-2, ελαχιστοποιεί τις ανεπιθύμητες GI και νεφρικές παρενέργειες που παρατηρούνται με τα τρέχοντα εμπορικά μη-στεροειδή αντιφλεγμονώδη φάρμακα (NSAΙDs).
CY20061100599T 1997-08-22 2006-05-09 Αναστολεις της βιοσυνθεσης της συνθασης του ενδοϋπεροξειδιου η της προσταγλανδινης CY1105027T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91866197A 1997-08-22 1997-08-22
PCT/US1998/017618 WO1999010332A1 (en) 1997-08-22 1998-08-20 Prostaglandin endoperoxide h synthase biosynthesis inhibitors

Publications (1)

Publication Number Publication Date
CY1105027T1 true CY1105027T1 (el) 2010-03-03

Family

ID=25440748

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20061100599T CY1105027T1 (el) 1997-08-22 2006-05-09 Αναστολεις της βιοσυνθεσης της συνθασης του ενδοϋπεροξειδιου η της προσταγλανδινης

Country Status (10)

Country Link
EP (1) EP1005460B1 (el)
JP (1) JP2002511887A (el)
AT (1) ATE319691T1 (el)
CA (1) CA2294548A1 (el)
CY (1) CY1105027T1 (el)
DE (1) DE69833774T2 (el)
DK (1) DK1005460T3 (el)
ES (1) ES2260846T3 (el)
PT (1) PT1005460E (el)
WO (1) WO1999010332A1 (el)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6307047B1 (en) 1997-08-22 2001-10-23 Abbott Laboratories Prostaglandin endoperoxide H synthase biosynthesis inhibitors
CN1142148C (zh) 1997-11-19 2004-03-17 兴和株式会社 新颖的哒嗪衍生物和含有其作为有效成分的药物
TWI241295B (en) 1998-03-02 2005-10-11 Kowa Co Pyridazine derivative and medicine containing the same as effect component
KR100666838B1 (ko) * 1998-10-27 2007-01-11 아보트 러보러터리즈 프로스타글란딘 엔도퍼옥사이드 ｈ 신타제 생합성 억제제 및 이를 포함하는 약제학적 조성물
JP2000247959A (ja) 1999-02-26 2000-09-12 Kowa Co ピリダジン−３−オン誘導体及びこれを含有する医薬
NZ519781A (en) 1999-12-23 2004-04-30 Nitromed Inc Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use
US6664256B1 (en) 2000-07-10 2003-12-16 Kowa Co., Ltd. Phenylpyridazine compounds and medicines containing the same
CA2518227A1 (en) 2003-03-18 2004-09-30 Kowa Co., Ltd Water-soluble phenylpyridazine derivative and medicine containing the same
EP2266585B1 (en) 2003-05-07 2013-06-26 Osteologix A/S Water-soluble strontium salts for use in treatment of cartilage and/or bone conditions
JPWO2005012259A1 (ja) * 2003-07-30 2007-09-27 興和株式会社 オステオポンチン産生抑制方法
DE102004010207A1 (de) 2004-03-02 2005-09-15 Aventis Pharma S.A. Neue 4-Benzimidazol-2-yl-pyridazin-3-on-Derivate
EP2591784B1 (en) 2005-05-10 2016-09-14 Intermune, Inc. Pyridine-2-one-derivatives as modulators of stress-activated protein kinase system
DE102005057924A1 (de) * 2005-12-05 2007-06-06 Merck Patent Gmbh Pyridazinonderivate
DE102006037478A1 (de) * 2006-08-10 2008-02-14 Merck Patent Gmbh 2-(Heterocyclylbenzyl)-pyridazinonderivate
DE102007025718A1 (de) * 2007-06-01 2008-12-04 Merck Patent Gmbh Pyridazinonderivate
US8304413B2 (en) 2008-06-03 2012-11-06 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
KR102373700B1 (ko) 2014-04-02 2022-03-11 인터뮨, 인크. 항섬유성 피리디논
IL305573A (en) 2021-03-15 2023-10-01 Saul Yedgar Hyaluronic acid conjugated with dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (NSAIDs) for the treatment or suppression of inflammatory diseases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3934436A1 (de) * 1989-06-01 1991-04-18 Thomae Gmbh Dr K 2-hydroxy-n-propylamine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung

Also Published As

Publication number Publication date
ES2260846T3 (es) 2006-11-01
ATE319691T1 (de) 2006-03-15
EP1005460B1 (en) 2006-03-08
WO1999010332A1 (en) 1999-03-04
EP1005460A1 (en) 2000-06-07
DE69833774D1 (en) 2006-05-04
PT1005460E (pt) 2006-07-31
JP2002511887A (ja) 2002-04-16
DK1005460T3 (da) 2006-07-10
DE69833774T2 (de) 2007-04-26
CA2294548A1 (en) 1999-03-04

Similar Documents

Publication Publication Date Title
CY1105027T1 (el) Αναστολεις της βιοσυνθεσης της συνθασης του ενδοϋπεροξειδιου η της προσταγλανδινης
ATE302759T1 (de) Prostaglandin endoperoxyde h synthase biosynthese inhibitoren
CA2299300A1 (en) Arylpyridazinones as prostaglandin endoperoxide h synthase bisoynthesis inhibitors
BRPI0011172B8 (pt) derivados do 4,5-diaril-3(2h)-furanona como inibidores de ciclooxigenase-2
CY1115634T1 (el) Μεσα ανταγωνιστικης επιλεκτικης συνδεσης της πρωτεϊνης συνδεσης οστεοπροτεγερινης
ATE385256T1 (de) Adenovirale vektoren spezifisch für zellen, welche alpha-fetoprotein exprimieren, sowie methoden zu deren verwendung
NO20001359D0 (no) Synergistisk analgetisk kombinasjon av opioid analgetikum og cyklooksigenase-2 inhibitor
DE69942459D1 (de) Isolierte nukleinsäuremoleküle die t-zellen induzierbare faktoren kodieren (tif), kodierte proteine und ihre anwendung
DE69906311D1 (de) Diarylbenzopyranderivate als cyclooxygenase-2-inhibitoren
Devaux et al. Lipopolysaccharide-induced increase of prostaglandin E2 is mediated by inducible nitric oxide synthase activation of the constitutive cyclooxygenase and induction of membrane-associated prostaglandin E synthase
CY1109280T1 (el) Συμπλοκα του λιθιου με ν-(1-υδροξυμεθυλο-2,3-διυδροξυπροπυλο)-1,4,7-τρισκαρβοξυμεθυλο-1,4,7,10-τετρααζακυκλοδωδεκανιο, η παραγωγη και χρηση αυτων
WO2002010393A3 (en) Isolated nucleic acid molecules which encode t cell inducible factors, or interleukin-21, the proteins encoded, and uses thereof
TR200000478T2 (tr) Prostaglandin endoperoksit H sentaz biyosentezi inhibitörleri olarak arilpiridazinonlar.
DE60206044D1 (de) Speissschutzmuffe
EA199800675A1 (ru) Дифенилстильбены как пролекарства к ингибиторам циклооксигеназы(сох-2)
ATE244232T1 (de) (methylsulfonyl)phenyl-2-(5h)-furanone mit sauerstoff-bindung als cox-2-hemmer
BR0317864A (pt) Bateria
ATE366260T1 (de) Kalzium-aktivierte kaliumkanäle mit niedriger und mittlerer leitfähigkeit und ihre verwendungen.
AR025049A1 (es) Ciclooxigenasa-1 (cox-1) y ciclooxigenasa-2 (cox-2) caninas.
CY1106814T1 (el) Εκλεκτικη διαδικασια οξειδωσης με ενισχυμενη ασφαλεια
CY1106355T1 (el) Πρωτεϊνη συνδεομενη με αποπτινη
BG100697A (en) Fluoropropylthiazoline derivative and herbicide
EP0205067A3 (en) Herbicidal imidazolidinone derivatives
TR199901701T2 (xx) �nsektisidal oksadizin bile�ikleri.
Flower In Vitro Cyclo-oxygenase Expression and Activity Protocols: Introduction to Part I